Alpine Immune Sciences Revenue and Competitors

Claim your profile

Seattle, WA USA

Location

#5692

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Alpine Immune Sciences's estimated annual revenue is currently $6.8M per year.(i)
  • Alpine Immune Sciences received $48.0M in venture funding in June 2016.
  • Alpine Immune Sciences's estimated revenue per employee is $66,863
  • Alpine Immune Sciences's total funding is $225.3M.

Employee Data

  • Alpine Immune Sciences has 102 Employees.(i)
  • Alpine Immune Sciences grew their employee count by 44% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2.8M18N/AN/AN/A
#2
$21.4M138-4%N/AN/A
#3
$3.4M22N/AN/AN/A
#4
$4.5M29N/AN/AN/A
#5
$3.3M21N/AN/AN/A
#6
$14.3M0N/A$25.3MN/A
#7
$13.2M85-3%$35MN/A
#8
$1.9M12N/AN/AN/A
#9
$2M13N/AN/AN/A
#10
N/A0N/A$99MN/A

Founded in 2015 by a team responsible for the FDA's approval of the world's first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies, Alpine Immune Sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases. Traded on NASDAQ under ticker ALPN.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$225.3M

Total Funding

102

Number of Employees

$6.8M

Revenue (est)

44%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Alpine Immune Sciences News

2022-04-13 - Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Expected to ...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Expected to Post Earnings of -$0.17 Per Share. Posted by admin on Apr 13th, 2022.

2022-04-06 - Alpine Immune Sciences Publishes Key Preclinical Rationale ...

Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint...

2022-04-06 - Alpine Immune Sciences Announces Company Presentation ...

Alpine Immune Sciences Announces Company Presentation and Update on AACR Investor Event. - AACR Investor Event time change to 6:30 p.m. ET - -...

2019-09-08 - Is Alpine Immune Sciences (NASDAQ:ALPN) Weighed On By Its Debt Load?

We can see that Alpine Immune Sciences, Inc. (NASDAQ:ALPN) does use debt in its business. But should shareholders be worried about its ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$27.5M1025%N/A
#2
$13.3M102-10%N/A
#3
$27.5M102-15%N/A
#4
$21.6M103N/AN/A
#5
$21.2M10422%$18.8M

Alpine Immune Sciences Funding

DateAmountRoundLead InvestorsReference
2016-06-14$48.0MAOrbiMed AdvisorsArticle